A chimeric peptide of intestinal trefoil factor containing cholesteryl ester transfer protein B cell epitope significantly inhibits atherosclerosis in rabbits after oral administration

Peptides

Volumn 32, Issue 4, 2011, Pages 790-796

  Qi, Gaofu ^a   Li, Jingjing ^a   Wang, Shengying ^a   Xin, Shanshan ^a   Du, Peng ^b   Zhang, Qingye ^a   Zhao, Xiuyun ^a  

^a HUAZHONG AGRICULTURAL UNIVERSITY   (China)

^b HUBEI UNIVERSITY   (China)

Author keywords

Atherosclerosis; CETP; Intestinal trefoil factor; Oral peptide vaccine

Indexed keywords

ANTIBODY; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN ANTIBODY; CYTOKINE; EPITOPE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTESTINAL TREFOIL FACTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEPTIDE; PROTEINASE; TETANUS TOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; B LYMPHOCYTE; BLOOD LEVEL; CHIMERA; CONTROLLED STUDY; EXPERIMENTAL RABBIT; FEMALE; HELPER CELL; HYPERPLASIA; IMMUNIZATION; INTESTINE FLUID; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; PROTEIN STRUCTURE;

ADMINISTRATION, ORAL; AMINO ACID SEQUENCE; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; MOLECULAR SEQUENCE DATA; PEPTIDES; RABBITS;

ANIMALIA; LOTUS; ORYCTOLAGUS CUNICULUS;

EID: 79952818116     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.12.014     Document Type: Article

References (29)

1. Barter P. CETP and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2029.
2. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22. (Pubitemid 350146106)
3. Clark RW, Ruggeri RB, Cunningham D, Bamberger MJ. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006;47:537-52. (Pubitemid 43345595)
4. De Grooth GJ, Klerkx AHEM, Stroes ESG, Stalenhoef AFH, Kastelein JJP, Kuivenhoven JA. A review of CETP and its relation to atherosclerosis. J Lipid Res 2004;45:1967-74. (Pubitemid 40990890)
5. Eriksson K, Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 2002;14:666-72.
6. Grewal HMS, Karlsen TH, Vetvik H, Åhreǐn C, Gjessing HK, Sommerfelt H, et al. Measurement of specific IgA in faecal extracts and intestinal lavage fluid for monitoring of mucosal immune responses. J Immunol Methods 2000;23:953-62.
7. Hamilton JA, Deckelbaum RJ. Crystal structure of CETP: new hopes for raising HDL to decrease risk of cardiovascular disease? Nat Struct Mol Biol 2007;14:95-7.
8. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11:S45-53.
9. Joy TR, Hegele RA. The failure of torcetrapib: what have we learned? Br J Pharmacol 2008;154:1379-81.
10. Kindon H, Pothoulakis C, Thim L, Lynch DK, Podolsky DK. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 1995;109:516-23.
11. Kjellev S, Vestergaard EM, Nexø E, Thygesen P, Eghøj MS, Jeppesen PB, et al. Pharmacokinetics of trefoil peptides and their stability in gastrointestinal contents. Peptides 2007;28:1197-206. (Pubitemid 46850775)
12. Lauterslager TGM, Hilgers LAT. Efficacy of oral administration and oral intake of edible vaccines. Immunol Lett 2002;84:185-90. (Pubitemid 35299422)
13. McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001;19:2657-60. (Pubitemid 32234285)
14. McSorley SJ, Garside P. Vaccination by inducing oral tolerance? Immunol Today 1999;20:555-60.
15. Moravec T, Schmidt MA, Hermanb EM, Woodford-Thomas T. Production of Escherichia coli heat labile toxin (LT) B subunit in soybean seed and analysis of its immunogenicity as an oral vaccine. Vaccine 2007;25:1647-57. (Pubitemid 46108208)
16. Muskett FW, May FEB, Westley BR, Feeney J. Solution structure of the disulfide-linked dimer of human intestinal trefoil factor (TFF3): the intermolecular orientation and interactions are markedly different from those of other dimeric trefoil proteins. Biochemistry 2003;42:15139-47. (Pubitemid 38031713)
17. Niikura M, Takamura S, Kim G, Kawai S, Saijo M, Morikawa S, et al. Chimeric recombinant hepatitis E virus-like particles as an oral vaccine vehicle presenting foreign epitopes. Virology 2002;293:273-80.
18. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-7. (Pubitemid 30469005)
19. Panina-Borgignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989;19:2237-42. (Pubitemid 20024747)
20. Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murgue B, Debeaumont M, et al. Identification of human intestinal trefoil factor: goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993;268:6694-702. (Pubitemid 23099375)
21. Qi G, Long J, Zhao X, Liu W, Wu J, Liu J. Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sci 2005;77:2690-702.
22. Rittershaus CW, Miller DP, Thomas LJ, Picard MD, Honan CM, Emmett CD, et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2106-12.
23. Russell-Jones GJ. Oral vaccine delivery. J Control Release 2000;65:49-54. (Pubitemid 30122914)
24. Tall AR. Plasma cholesteryl ester transfer protein and high-density lipoproteins: new insights from molecular genetic studies. J Intern Med 1995;237:5-12.
25. Tall AR, Yvan-Charvet L, Wang N. The failure of torcetrapib. Was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 2007;27:257.
26. Thim L. Trefoil peptides: from structure to function. Cell Mol Life Sci 1997;53:888-903. (Pubitemid 28021502)
27. Van Ginkel FW, Jackson RJ, Yuki Y, McGhee JR. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000;165:4778-82.
28. Wikingsson LD, Sjöholm I. Polyacryl starch microparticles as adjuvant in oral immunisation, inducing mucosal and systemic immune responses in mice. Vaccine 2002;20:3355-63. (Pubitemid 35245819)
29. Yuan X, Yang X, Cai D, Mao D, Wu J, Li Z, et al. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2008;26:3727-34.